| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA191: Capecitabine for the treatment of advanced gastric cancer |
|
Medicine details |
|
| Medicine name | capecitabine (Xeloda®) |
| Formulation | 150 mg, 500 mg film coated tablets |
| Reference number | 74 |
| Indication | TA191: Capecitabine for the treatment of advanced gastric cancer |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/11/2008 |
| NICE guidance | TA191: Capecitabine for the treatment of advanced gastric cancer |